Primary Immune Thrombocytopenia
Conditions
Brief summary
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with primary chronic ITP.
Detailed description
This study consisted of a randomized, double-blind, placebo-controlled, 26-week treatment period, sequentially followed by an open-label, single-arm, 12-week treatment period, and an additional 4-week safety follow-up period.
Interventions
DRUGQL0911
The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
DRUGPlacebo comparator
The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥18 years old; * Diagnosed primary ITP for at least 12 months; * Had received at least one first-line ITP treatment with no response or recurrence after treatment; * Had a platelet count \<30×10\^9/L within 48 hours before the first dose; * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; * Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.
Exclusion criteria
* Had a history of bone marrow stem cell abnormalities or myelodysplastic syndrome other than ITP-specific changes. * Had arterial thrombosis, or venous thromboembolism; severe cardiovascular diseases; malignant tumors; secondary thrombocytopenia caused by autoimmune diseases. * Underwent splenectomy within 12 weeks before the first dose; * Had received ITP treatments (including rescue treatment) within 2 weeks before the first dose; * Had received romiplostim (Nplate®) or eltrombopag (Revolade®), rhTPO or other agents that stimulate TPO receptors (also known as c-Mpl), and hematopoietic growth factors (HGFs) within 4 weeks before the first dose; * Had received antineoplastic agents within 8 weeks before the first administration, but when treating ITP with hypomethylating agents (HMA) such as decitabine, a 4-week washout period was acceptable, as judged by the investigator; * Had received antibody-based therapies within 14 weeks before the first dose; 8) had serum creatinine or total bilirubin \>1.5 upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) \>3 ULN, hemoglobin \< 100g/L, absolute neutrophil count \<1.5x10\^9/L; * Had prothrombin time (PT) or prothrombin time-international normalized ratio (PT-INR) or activated partial thromboplastin time (APTT) exceeded 20% of the reference range of normal values.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of patients achieving durable platelet response at week 24 during the double-blind treatment period | 24weeks |
Secondary
| Measure | Time frame |
|---|---|
| proportion of patients with weekly platelet responses within 24 weeks of treatment; | 24weeks |
| Proportion of patients who achieved platelet count ≥ 30 × 10^9/L at least a two-fold increase from baseline platelet count without bleeding during the 24-week double-blind period; | 24weeks |
Countries
China
Outcome results
None listed